ArticleMolecular biology reports2026
Comparative genomic and phenotypic analysis of Streptomyces rochei SOSIST-3 isolated from the Southern Ocean.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe genus Streptomyces are renowned for their ability to produce a wide array of antimicrobial compounds. However, their biosynthetic potential in polar environments, particularly the Southern Ocean, remains largely unexplored. METHODS AND
resultsIn this study, we isolated a Streptomyces strain SOSIST-3 from the Indian sector of the Southern Ocean. Using a combination of physiological assays and phylogenomic analysis, we identified the strain as Streptomyces rochei. The genome of this strain is 8.59 Mb in size, with a GC content of 71%, and encodes 7,728 genes, including 590 core genes. Analysis of secondary metabolic potential using antiSMASH predicted 43 biosynthetic gene clusters, of which 19 showed low or no similarity to known clusters, indicating the presence of potentially novel biosynthetic pathways. Comparative genomic analysis with closely related Streptomyces using BiG-SCAPE revealed that strain SOSIST-3 harbours the most diverse BGC repertoire, encompassing nine different classes and a total of 21 biosynthetic genes. Antimicrobial activity assay demonstrated strong inhibitory effects against several pathogens. The highest inhibition was observed against Aeromonas hydrophila ATCC 7966 (23.8 ± 1.51 mm), followed by Klebsiella pneumoniae ATCC 13,882 (18 ± 1.21 mm), Staphylococcus aureus ATCC 29,213 (12.6 ± 1.19 mm), Pseudomonas aeruginosa ATCC 27,853 (12.4 ± 1.12 mm), and Escherichia coli. ATCC 25,922 (12.2 ± 1.04 mm).
conclusionsThe findings highlight the untapped potential of Streptomyces from polar regions for antimicrobial discovery, with S. rochei SOSIST-3 emerging as a promising candidate for bioprospecting.
Indexed as
Identifiers
41543634What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.